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Abstract
Background: It is not clear whether clinical practice guidelines (CPGs) and consensus 
statements (CSs) are adequately promoting shared decision making (SDM).
Objective: To evaluate the recommendations about SDM in CPGs and CSs concern-
ing breast cancer (BC) treatment.
Search strategy: Following protocol registration (Prospero no.: CRD42018106643), 
CPGs and CSs on BC treatment were identified, without language restrictions, 
through systematic search of bibliographic databases (MEDLINE, EMBASE, Web of 
Science, Scopus, CDSR) and online sources (12 guideline databases and 51 profes-
sional society websites) from January 2010 to December 2019.
Inclusion criteria: CPGs and CSs on BC treatment were selected whether published 
in a journal or in an online document.
Data extraction and synthesis: A 31-item SDM quality assessment tool was devel-
oped and used to extract data in duplicate.
Main results: There were 167 relevant CPGs (139) and CSs (28); SDM was reported 
in only 40% of the studies. SDM was reported more often in recent publications after 
2015 (42/101 (41.6 %) vs 46/66 (69.7 %), P = .0003) but less often in medical journal 
publications (44/101 (43.5 %) vs 17/66 (25.7 %), P = .009). In CPGs and CSs with 
SDM, only 8/66 (12%) met one-fifth (6 of 31) of the quality items; only 14/66 (8%) 
provided clear and precise SDM recommendations.
Discussion and conclusions: SDM descriptions and recommendations in CPGs and 
CSs concerning BC treatment need improvement. SDM was more frequently re-
ported in CPGs and CSs in recent years, but surprisingly it was less often covered in 
medical journals, a feature that needs attention.
K E Y W O R D S
breast cancer, breast cancer treatment, clinical practice guidelines, consensus, shared 
decision making
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1  | INTRODUC TION
Breast cancer (BC) is the most common cancer in women, with 2.1 
million new cases each year (25% of all female cancers), and it also 
causes the greatest number (about 670000 in 2018, 15%) of can-
cer-related deaths among women1,2. Mortality and morbidity from 
BC have decreased in recent years thanks to early diagnosis and 
the combination of new treatments in a growing array of different 
strategies3,4. The best BC treatment must be personalized4,5, and 
choosing the ideal approach requires a high degree of specialization, 
scientific-technical updating, multidisciplinary coordination and pa-
tient participation6-9.
This participation in shared decision making (SDM) is considered 
a keystone in the achievement of sustainable high-quality cancer 
care, and it becomes especially important when separate treatment 
options with overall similar potential can yield very different results 
depending on patients' preferences9,10. In developed countries, SDM 
is a legal obligation11-13, and it has been shown to increase the sat-
isfaction of the patient9, improve cost-effectiveness9 and reduce 
malpractice lawsuit14. It is claimed to be a keystone to guarantee 
good quality cancer care9, and it is highly recommended by medical 
associations15-17.
The implementation of SDM has persistent barriers18-22, and 
it is still poor23,24. Many authors have proposed strategies for 
promotion and practical application of SDM10,21,25-28. A three-
step model introducing choice, describing options and exploring 
preferences has been suggested10. Another proposal involves 
encouraging patients to make their own care goals that clini-
cians translate into treatment plans21,25. Option Grids and other 
decision aids are thought to make the SDM process easier26,27. 
Measuring SDM as a quality indicator and reimbursing profes-
sionals that actually use SDM have been floated as another idea 
involving incentivization28.
This important subject should be adequately covered in clin-
ical practice guidelines (CPGs) and consensus statements (CSs), 
especially in those that are published in a medical journal. The aim 
of this systematic review was to evaluate the characteristics of 
CPGs and CSs with SDM compared to those without, to develop 
an SDM quality assessment tool and to collate the specific infor-
mation and recommendations about SDM concerning BC treat-
ment in women.
2  | METHODS
This systematic review was carried out following protocol regis-
tration (Prospero No: CRD42018106643) and using a prospective 
protocol developed based on recommended methods for literature 
searches and assessment of guidelines. During the course of the 
work, no SDM assessment tool was identified in the literature, so 
we developed such a tool for data extraction in our work. It was 
reported according to the preferred reporting items for systematic 
reviews and meta-analyses (PRISMA)29,30 (see Appendix 1).
2.1 | Data sources and searches
A systematic search combining MeSH terms "shared decision 
making", "clinical practice guidelines", "guidelines", "consensus", 
“breast cancer”, “breast cancer treatment” and including word vari-
ants was conducted using MEDLINE covering the period January 
2010 to December 2019, without language restrictions. We fur-
ther searched online databases (EMBASE, Web of Science, Scopus, 
CDSR, etc.), 12 guideline-specific databases and 51 websites of rel-
evant professional societies (see Appendix ). For completeness, we 
searched on the World Wide Web and the bibliographies of known 
relevant publications to identify additional studies of relevance to 
the review.
2.2 | Study selection and data extraction
We included CPGs and CSs about BC management, produced by 
governmental agencies or national and international professional or-
ganizations and societies. We excluded CPGs and CSs about screen-
ing and diagnosis, obsolete guidelines replaced by updates from the 
same organization, and CPG and CSs for education and information 
purpose only.
Two reviewers (MMC and IMMN) independently considered 
the potential eligibility of each of the titles and abstracts from the 
citations and requested full-text versions. Working independently, 
reviewers assessed the full text to confirm eligibility. Disagreements 
were resolved by consensus or arbitration by a third reviewer (MMD). 
Duplicate articles were identified and removed. Where multiple ver-
sions of a CPG or CS were retrieved, the most recent version was 
reviewed. Data were extracted from selected CPGs and CSs in dupli-
cate, independently. The intraclass correlation coefficient (ICC) was 
used to assess consistency between reviewers in data extraction, 
and the reliability level was excellent >0.9031. Authoritative guid-
ance32 on systematic review methods recommends inter-reviewer 
reliability assessment that is designed to compare measurements 
obtained by two or more reviewers extracting data from the same 
papers.
2.3 | Guideline quality assessment and 
data extraction
We conducted a search to identify a quality assessment tool for 
SDM. No relevant tools were identified, so we constructed one 
using consensus to create a checklist from a long list of items iden-
tified in the literature searches. The quality of CPGs and CSs for 
SDM to manage patients with BC was independently evaluated by 
two different reviewers (MMC and IMMN) using a piloted data ex-
traction form. Disagreements between the two authors (MMC and 
IMMN) over the risk of bias for particular studies were solved by 
group discussion involving an arbitrator (MMD) who took the final 
decision.
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2.4 | Data synthesis
Two authors (MMC and IMMN) synthesized the data extracted to 
summarize key information within using a piloted data extraction 
form concerning characteristics of CPGs and CSs with the SDM in-
formation and recommendations contained within them. Rate data 
were compared using chi-square test to examine whether CPGs and 
CSs with SDM were different to those without SDM.
3  | RESULTS
3.1 | Study selection
Of the 4116 potential citations identified, a total of 167 documents 
(139 CPGs33-171 and 28 CSs172-199) were identified for final evalua-
tion (Figure 1). ICC for reviewer agreement was 0.97.
3.2 | Development of a quality assessment tool
Individual quality items were scattered across a number of tools 
for guidelines assessment 200,201. A long list of items was com-
piled and presented to a group of four BC and SDM specialists in 
a consensus meeting. This process including several revisions and 
iterations which led to a 31-item checklist grouped into thirteen 
domains (see Appendix ). Of these, 68% (n = 21) were identified 
from the AGREE201 and 48% (n = 15) from the RIGHT200 tools. 
Only 13% (n = 4) of these items did not appear in any of these two 
tools. However, the expert consensus advised their inclusion after 
examining other literature in the bibliography of interest about 
SDM9,21,24,25,27. The consensus meeting following approval of the 
31-item checklist recommended that each item be examined for 
compliance. The greater the percentage of items complied with, the 
greater the quality for SDM in the CPG or CS assessed. The consen-
sus meeting did not recommend the construction of a formal score 
or a cut point for defining quality.
3.3 | Study characteristics
The distribution by countries of CPGs and CSs that speak about 
SDM was irregular (Figure 1). Europe stood out with a total of 25 
CPGs and CSs (38%). North America developed 29 (44%) CPGs and 
CSs (USA: 19 and Canada: 10). South America released six (9%) CPGs 
and CSs (Colombia, Venezuela, Mexico, Peru and two from Costa 
Rica). Asia also carried out three (5%) CPGs and CSs (Japan, India 
and Malaysia). Oceania has developed also three (5%)CPGs and CSs: 
two from Australia and one from New Zealand. The basic character-
istics of the CPGs and CSs including organization, country and year 
of release are summarized in Table 1. The duration since last update 
of each CPGs or CSs varied. Some AGO46,48,49,59, all the NCCN149-153 
and one of the AHS89 CPGs, and ESMO178 and the Mexican CS173 
were the most recently updated (highlighted in Table 2). Overall, the 
last update of the CPGs and CSs with SDM was more recent than that 
of those without SDM (mean 45 months (range: 3-115) vs 52 months 
(range: 3-116), P < .001). In this comparison, 9% (n = 15/167) did not 
specify the month of updated but only the year. SDM was reported 
more often in recent CPGs and CSs published after 2015 (42/101 
(42.0%) vs 46/66 (69.7%), P =.0003) but less often in CPGs and 
CSs published in medical journal (44/101 (43.5%) vs 17/66 (25.7%), 
P = .009) (Table 3).
F I G U R E  1   Flow diagram for study 
selection of CPGs and CSs
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TA B L E  1   Description of the CPGs and CSs (n = 167) selected for the systematic review on the quality of reporting concerning SDM in BC 
treatment
Abbreviated name Entity Country Year
Name of the CPG
1 Guidelines on the diagnosis and treatment of breast cancer 
(2011 edition)32
Chinese BC CPG32 CMH China 2012
2 Chinese guidelines for diagnosis and treatment of breast 
cancer 201833
Chinese BC diagnosis 
treatment33
NHCPRC China 2018
3 The Japanese Breast Cancer Society Clinical Practice Guideline 
for radiation treatment of breast cancer, 2015 edition34
Japanese RT BC CPG34 JBCS Japan 2015
4 The Japanese Breast Cancer Society Clinical Practice Guideline 
for systemic treatment of breast cancer, 2015 edition35
Japanese systemic BC CPG35 JBCS Japan 2015
5 2013 clinical practice guidelines (The Japanese Breast Cancer 
Society): history, policy and mission36
Japanese treatment BC 
CPG36
JBCS Japan 2014
6 Singapore Cancer Network (SCAN) Guidelines for Adjuvant 
Trastuzumab Use in Early Stage HER2 Positive Breast 
Cancer37
SCAN early BC37 SCAN Singapore 2015
7 Singapore Cancer Network (SCAN) Guidelines for 
Bisphosphonate Use in the Adjuvant Breast Cancer Setting38
SCAN adjuvant BC 
treatment38
SCAN Singapore 2015
8 Breast cancer in women: diagnosis, treatment and follow-up39 KCE BC CPG39 KCE Belgium 2015
9 Early breast cancer: ESMO Clinical Practice Guidelines for 
diagnosis, treatment and follow-up40
ESMO BC 201940 ESMO Europe 2019
10 International guidelines for management of metastatic breast 
cancer (MBC) from the European School of Oncology (ESO)41
ESO MBC41 ESO Europe 2013
11 The European Society of Breast Cancer Specialists 
recommendations for the management of young women with 
breast cancer42
EUSOMA 201242 EUSOMA Europe 2012
12 AGO Recommendations for the Diagnosis and Treatment of 
Patients with Early Breast Cancer: Update 201943
AGO early BC43 AGO Germany 2019
13 Lesions of Uncertain Malignant Potential (B3) (ADH, LIN, FEA, 
Papilloma, Radial Scar)44
AGO uncertain lesions44 AGO Germany 2019
14 Ductal Carcinoma in Situ (DCIS)45 AGO DCIS45 AGO Germany 2019
15 Breast Cancer Surgery Oncological Aspects46 AGO oncological46 AGO Germany 2019
16 Oncoplastic and Reconstructive Surgery47 AGO oncoplastic47 AGO Germany 2019
17 Adjuvant Endocrine Therapy in Pre- and Postmenopausal 
Patients48
AGO adjuvant endocrine48 AGO Germany 2019
18 Adjuvant Cytotoxic and Targeted Therapy49 AGO cytotoxic49 AGO Germany 2019
19 Neoadjuvant (Primary) Systemic Therapy50 AGO neoadjuvant50 AGO Germany 2019
20 Adjuvant Radiotherapy51 AGO RT51 AGO Germany 2019
21 Therapy Side Effects52 AGO side effects52 AGO Germany 2019
22 Supportive Care53 AGO supportive care53 AGO Germany 2019
23 Breast Cancer: Specific Situations54 AGO-specific situations54 AGO Germany 2019
24 Breast Cancer Follow-Up55 AGO follow-up55 AGO Germany 2019
25 Loco-Regional Recurrence56 AGO recurrence56 AGO Germany 2019
26 Endocrine and “Targeted” Therapy in Metastatic Breast 
Cancer57
AGO endocrine MBC57 AGO Germany 2019
27 Chemotherapy With or Without Targeted Drugs* in Metastatic 
Breast Cancer58
AGO CT MBC58 AGO Germany 2019
28 Osteooncology and Bone Health59 AGO osteooncology59 AGO Germany 2019
29 Specific Sites of Metastases60 AGO-specific MBC60 AGO Germany 2019
30 CNS Metastases in Breast Cancer61 AGO CNS MBC61 AGO Germany 2019
(Continues)
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Abbreviated name Entity Country Year
31 Complementary Therapy Survivorship62 AGO survivorship62 AGO Germany 2019
32 Diagnosis and Treatment of Patients with Primary and 
Metastatic Breast Cancer63
AGO primary MBC63 AGO Germany 2018
33 AGO Recommendations for the Diagnosis and Treatment 
of Patients with Advanced and Metastatic Breast Cancer: 
Update 201864
AGO advanced MBC64 AGO Germany 2018
34 DEGRO practical guidelines for radiotherapy of breast cancer 
VI: therapy of locoregional breast cancer recurrences65
DEGRO BC recurrences65 2014
35 DEGRO practical guidelines: radiotherapy of breast cancer I. 
Radiotherapy following breast conserving therapy for invasive 
breast cancer. 66
DEGRO RT conserving BC66 DEGRO Germany 2013
36 DEGRO practical guidelines for radiotherapy of breast cancer 
IV. Radiotherapy following mastectomy for invasive breast 
cancer67
DEGRO RT mastectomy BC67 DEGRO Germany 2014
37 DEGRO practical guidelines: radiotherapy of breast cancer III—
radiotherapy of the lymphatic pathways68
DEGRO RT lymphatic68 DEGRO Germany 2014
38 Diagnosis, staging and treatment of patients with breast 
cancer. National Clinical Guideline No. 769
NCCP69 NCCP Ireland 2015
39 Breast cancer70 Richtlijnendatabase BC70 Richtlijnen Netherlands 2018
40 Dutch breast reconstruction guideline71 Dutch BCR71 DPRS Netherlands 2017
41 Breast Cancer72 IKNL BC72 IKNL Netherlands 2012
42 Cáncer de mama/ Breast Cancer73 Fisterra BC73 Fisterra Spain 2017
43 SEOM clinical guidelines in early-stage breast cancer74 SEOM early stage74 SEOM Spain 2018
44 SEOM clinical guidelines in advanced and recurrent breast 
cancer75
SEOM advanced BC75 SEOM Spain 2018
45 SEOM clinical guidelines in metastatic breast cancer76 SEOM MBC76 SEOM Spain 2015
46 SEOM clinical guidelines in Hereditary Breast and ovarian 
cancer77
SEOM hereditary BC77 SEOM Spain 2015
47 Abemaciclib with fulvestrant for treating hormone receptor-
positive, HER2-negative advanced breast cancer after 
endocrine the therapy78
NICE abemaciclib78 NICE UK 2019
48 Ribociclib with fulvestrant for treating hormone receptor-
positive, HER2-negative advanced breast cancer79
NICE ribociclib79 NICE UK 2019
49 Early and locally advanced breast cancer: diagnosis and 
management80
NICE early and advanced 
BC80
NICE UK 2018
50 Breast cancer81 NICE BC81 NICE UK 2011
51 Familial breast cancer: classification, care and managing breast 
cancer and related risks in people with a family history of 
breast cancer82
NICE familial BC82 NICE UK 2013
52 Breast reconstruction using lipomodelling after breast cancer 
treatment83
NICE lipomodelling83 NICE UK 2012
53 Gene expression profiling and expanded 
immunohistochemistry tests for guiding adjuvant 
chemotherapy decisions in early breast cancer management: 
MammaPrint, Oncotype DDX,X, IHC4 and Mammostrat84
NICE gene expression84 NICE UK 2013
54 Pertuzumab for the neoadjuvant treatment of HER2-positive 
breast cancer85
NICE pertuzumab BC85 NICE UK 2016
55 Intraoperative tests (RD-100i OSNA system and Metasin 
test) for detecting sentinel lymph node metastases in breast 
cancer86
NICE sentinel lymph86 NICE UK 2013
56 Breast reconstruction following prophylactic or therapeutic 
mastectomy for breast cancer87
AHS reconstruction BC87 AHS Canada 2017
TA B L E  1   (Continued)
(Continues)
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Abbreviated name Entity Country Year
57 Adjuvant systemic therapy for early stage (lymph node 
negative and lymph node positive) breast cancer88
AHS early BC88 AHS Canada 2018
58 Optimal use of taxanes in metastatic breast cancer (MBC)89 AHS MBC89 AHS Canada 2013
59 Adjuvant radiation therapy for invasive breast cancer90 AHS RT invasive90 AHS Canada 2015
60 Adjuvant radiation therapy for ductal carcinoma in situ91 AHS RT DCI91 AHS Canada 2015
61 Neo-adjuvant (pre-operative) therapy for breast cancer - 
general considerations 92
AHS neo-adjuvant92 AHS Canada 2014
62 The Role of Trastuzumab in Adjuvant and Neoadjuvant 





63 Surgical management of early-stage invasive breast cancer94 CCO surgical management 
BC 94
CCO Canada 2015
64 Breast irradiation in women with early stage invasive breast 
cancer following breast conserving surgery95
CCO RT95 CCO Canada 2016
65 The role of the taxanes in the management of metastatic 
breast cancer96
CCO taxane MBC96 CCO Canada 2011
66 Vinorelbine in stage IV breast cancer97 CCO vinorelbine97 CCO Canada 2012
67 The role of aromatase inhibitors in the treatment of 
postmenopausal women with metastatic breast cancer98
CCO aromatase inhibitor 
MBC98
CCO Canada 2012
68 Epirubicin, as a single agent or in combination, for metastatic 
breast cancer99
CCO epirubicin MBC99 CCO Canada 2011
69 Adjuvant taxane therapy for women with early-stage, invasive 
breast cancer100
CCO taxane adjuvant therapy 
BC100
CCO Canada 2011
70 Adjuvant systemic therapy for node-negative breast cancer101 CCO sQT for node-negative 
BC101
CCO Canada 2011
71 Adjuvant ovarian ablation in the treatment of premenopausal 
women with early stage invasive breast cancer102
CCO ovarian ablation early 
stage102
CCO Canada 2010
72 The role of gemcitabine in the management of metastatic 
breast cancer103
CCO gemcitabine103 CCO Canada 2011
73 The role of trastuzumab (herceptin) in the treatment of women 
with Her2/neu-overexpressing metastatic breast cancer104
CCO trastuzumab MBC104 CCO Canada 2010
74 Capecitabine in stage IV breast cancer105 CCO capecitabine105 CCO Canada 2011
75 The role of her2/neu in systemic and radiation therapy for 
women with breast cancer106
CCO her2/neu and RT 
treatment 106
CCO Canada 2012
76 Locoregional therapy of locally advanced breast cancer 
(LABC)107
CCO LABC107 CCO Canada 2014
77 The role of taxanes in neoadjuvant chemotherapy for women 
with non-metastatic breast cancer108
CCO taxane neoadjuvant 
therapy108
CCO Canada 2011
78 Optimal systemic therapy for early female breast cancer109 CCO early BC109 CCO Canada 2014
79 Use of adjuvant bisphosphonates and other bone-modifying 
agents in breast cancer110
CCO bone-modifying agent 
BC110
CCO Canada 2016
80 The Role of Aromatase Inhibitors in Adjuvant Therapy for 
Postmenopausal Women with Hormone Receptor-positive 
Breast Cancer111
CCO aromatase inhibitors 
HR + 111
CCO Canada 2012
81 Margin width in breast conservation Surgery112 ABS margin width BC112 ABS UK 2015
82 Antibiotic prophylaxis in breast surgery113 ABS AB prophylaxis113 ABS UK 2015
83 Management of The malignant axilla In early breast cancer114 ABS axila BC114 ABS UK 2015
84 Breast operation note Documentation115 ABS BC115 ABS UK 2015
85 Update on optimal duration of adjuvant antihormonal 
therapy116
ABS antihormonal therapy116 ABS UK 2015
TA B L E  1   (Continued)
(Continues)
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Abbreviated name Entity Country Year
86 Oncoplastic breast reconstruction117 ABS/BAPRAS oncoplastic117 ABS, 
BAPRAS
UK 2012
87 Acellular dermal matrix (ADM) assisted breast reconstruction 
procedures118
ABS/BAPRAS ADM118 ABS, 
BAPRAS
UK 2012
88 Breast Cancer Clinical Quality Performance Indicators119 SCT quality indicators119 SCT UK 2016
89 Treatment of primary breast cancer120 SIGN120 SIGN UK 2013
90 Lipomodelling Guidelines for Breast Surgery121 JGBSA lipomodelling121 JGBSA UK 2012
91 Performance and Practice Guidelines for the Use of 
Neoadjuvant Systemic Therapy in the Management of Breast 
Cancer122
ASBS NaQT BC122 ASBS USA 2017
92 Performance and Practice Guidelines for Mastectomy123 ASBS mastectomy123 ASBS USA 2014
93 Performance and Practice Guidelines for Breast-Conserving 
Surgery/Partial Mastectomy124
ASBS breast conserving124 ASBS USA 2014
94 Performance and Practice Guidelines for Axillary Lymph Node 
Dissection in Breast Cancer Patients125
ASBS ALD125 ASBS USA 2014
95 Performance and Practice Guidelines for Sentinel Lymph Node 
Biopsy in Breast Cancer Patients126
ASBS SLND126 ASBS USA 2014
96 Evidence-Based Clinical Practice Guideline: Autologous Breast 
Reconstruction with DIEP or Pedicled TRAM Abdominal 
Flaps127
ASPS DIEP and TRAM127 ASPS USA 2017
97 Use of Endocrine Therapy for Breast Cancer Risk Reduction: 
ASCO Clinical Practice Guideline Update128
ASCO endocrine therapy risk 
BC128
ASCO USA 2019
98 Postmastectomy Radiotherapy: An American Society of 
Clinical Oncology, American Society for Radiation Oncology, 
and Society of Surgical Oncology Focused Guideline 
Update129
ASCO postmastectomy RT129 ASCO USA 2017
99 Breast Cancer Surveillance Guidelines130 ASCO surveillance130 ASCO USA 2013
100 Selection of Optimal Adjuvant Chemotherapy and Targeted 
Therapy for Early Breast Cancer: ASCO Clinical Practice 
Guideline Focused Update131
ASCO treatment for early 
BC131
ASCO USA 2018
101 Systemic Therapy for Patients With Advanced Human 
Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 
ASCO Clinical Practice Guideline Update132
ASCO systemic therapy 
EGR2 BC132
ASCO USA 2018
102 Recommendations on Disease Management for Patients With 
Advanced Human Epidermal Growth Factor Receptor 2–
Positive Breast Cancer and Brain Metastases: ASCO Clinical 
Practice Guideline Update133
ASCO EGRF2 MBC133 ASCO USA 2018
103 Integrative Therapies During and After Breast Cancer 
Treatment: ASCO Endorsement of the SIO Clinical Practice 
Guideline134
ASCO BC treatment134 ASCO USA 2018
104 Chemotherapy and Targeted Therapy for Women With Human 
Epidermal Growth Factor Receptor 2–Negative (or unknown) 
Advanced Breast Cancer: American Society of Clinical 
Oncology Clinical Practice Guideline135
ASCO EGFR2 advanced 
BC135
ASCO USA 2014
105 Role of Bone-Modifying Agents in Metastatic Breast Cancer: 
An American Society of Clinical Oncology–Cancer Care 
Ontario Focused Guideline Update136
ASCO bone-modifying agent 
MBC136
ASCO USA 2017
106 Recommendations for Human Epidermal Growth Factor 
Receptor 2 Testing in Breast Cancer: American Society of 
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Abbreviated name Entity Country Year
107 Breast Cancer Follow-Up and Management After Primary 





108 Adjuvant Endocrine Therapy for Women With Hormone 
Receptor–Positive Breast Cancer: American Society of 
Clinical Oncology Clinical Practice Guideline Update on 
Ovarian Suppression139
ASCO ovarian suppression 
BC139
ASCO USA 2016
109 Role of Patient and Disease Factors in Adjuvant Systemic 
Therapy Decision Making for Early-Stage, Operable Breast 
Cancer: American Society of Clinical Oncology Endorsement 
of Cancer Care Ontario Guideline Recommendations140
ASCO factors in early BC140 ASCO USA 2016
110 Use of Adjuvant Bisphosphonates and Other Bone-Modifying 
Agents in Breast Cancer: A Cancer Care Ontario and 
American Society of Clinical Oncology Clinical Practice 
Guideline141
ASCO use bone-modifying 
agents BC141
ASCO USA 2017
111 Use of Biomarkers to Guide Decisions on Adjuvant Systemic 
Therapy for Women With Early-Stage Invasive Breast Cancer: 
American Society of Clinical Oncology Clinical Practice 
Guideline Focused Update142
ASCO biomarkers in early 
BC142
ASCO USA 2017
112 Use of Biomarkers to Guide Decisions on Systemic Therapy for 
Women With Metastatic Breast Cancer: American Society of 
Clinical Oncology Clinical Practice Guideline143
ASCO biomarkers in MBC143 ASCO USA 2019
113 American Society of Clinical Oncology Endorsement of the 
Cancer Care Ontario Practice Guideline on Adjuvant Ovarian 
Ablation in the Treatment of Premenopausal Women With 
Early-Stage Invasive Breast Cancer144
ASCO ovarian ablation BC144 ASCO USA 2011
114 American Society of Clinical Oncology/College of 
American Pathologists Guideline Recommendations for 
Immunohistochemical Testing of Estrogen and Progesterone 
Receptors in Breast Cancer145
ASCO hormonal BC145 ASCO USA 2010
115 Use of Pharmacologic Interventions for Breast Cancer Risk 
Reduction: American Society of Clinical Oncology Clinical 
Practice Guideline146
ASCO risk reduction BC146 ASCO USA 2013
116 Endocrine Therapy for Hormone Receptor–Positive Metastatic 
Breast Cancer: American Society of Clinical Oncology 
Guideline147
ASCO endocrine BC147 ASCO USA 2016
117 Invasive Breast Cancer. Basic resources. Version 1.2019148 NCCN invasive BC basic148 NCCN USA 2019
118 Invasive Breast Cancer. Core resources. Version 1.2019149 NCCN invasive BC core149 NCCN USA 2019
119 Invasive Breast Cancer. Enhanced resources. Version 1.2019150 NCCN invasive BC 
enhanced150
NCCN USA 2019
120 Breast Cancer. NCCN Evidence Blocks. Version 1.2019151 NCCN evidence block BC151 NCCN USA 2019
121 Breast Cancer. Version 3.2019152 NCCN BC152 NCCN USA 2019
122 Management of Breast Cancer (2nd Edition)153 MHM BC153 MHM Malaysia 2010
123 Influencing best practice in breast cancer154 Australia BC154 AG Australia 2016
124 Recommendations for staging and managing the axilla155 CA axilla155 CA Australia 2011
125 Recommendations for use of hypofractionated radiotherapy 
for early operable breast cancer156
CA RT156 CA Australia 2011
126 Recommendations for use of Bisphosphonates157 CA bisphosphonates157 CA Australia 2011
127 Recommendations for the management of early breast cancer 
in women with an identified BRCA1 or BRCA2 gene mutation 
or at high risk of a gene mutation158
CA management BC158 CA Australia 2014
128 Guía de Práctica Clínica AUGE Cáncer de Mama159 GPC Chile159 MSC Chile 2015
TA B L E  1   (Continued)
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Abbreviated name Entity Country Year
129 Guía de práctica clínica (GPC) para la detección temprana, 
tratamiento integral, seguimiento y rehabilitación del cáncer 
de mama160
GPC Colombia160 INC Colombia 2017
130 Guía de Práctica Clínica del Tratamiento para el Cáncer de 
Mama161
GPC Costa Rica161 IHCAI Costa Rica 2011
131 Guía de Práctica Clínica para el Tratamiento del Cáncer de 
Mama 162
GPC Perú162 DDSS Perú 2017
132 Guía para el Cáncer de Mama en Venezuela163 GPC Venezuela163 SAV Venezuela 2015
133 Management of Early Breast Cancer164 New Zealand BC164 MHNZ New Zealand 2014
134 The Screening, Diagnosis, Treatment, and Follow-Up of Breast 
Cancer165
Würzburg BC165 UHW Germany 2018
135 Breast cancer brain metastases: a review of the literature and a 
current multidisciplinary management guideline166
FESEO brain MBC166 FESEO Spain 2013
136 Cirugía de la Mama167 AEC BC167 AEC Spain 2017
137 NCA Breast Cancer Clinical Guidelines168 NCA BC168 NCA UK 2019
138 Breast Cancer: Management and Follow-Up169 BCMA management and 
follow-up169
BCMA Canada 2013
139 Clinical Guidelines for the Management of Breast Cancer170 WMCA BC 170 WMCA UK 2016
Name of the CS
140 Consenso costarricense sobre prevención, diagnóstico y 
tratamiento del cáncer mamario171
CS Costa Rica171 CMCCR Costa Rica 2016
141 Consenso Mexicano sobre diagnóstico y tratamiento del 
cáncer mamario 172
GPC México172 SSM México 2019
142 National consensus in China on diagnosis and treatment of 
patients with advanced breast cancer173
Chinese BC CS173 CECM China 2015
143 Practical consensus recommendations for hormone receptor-
positive Her2-negative advanced or metastatic breast 
cancer174
Indian ICON CS174 ICON India 2013
144 Indian Solutions for Indian Problems—Association of Breast 
Surgeons of India (ABSI) Practical Consensus Statement, 
Recommendations, and Guidelines for the Treatment of 
Breast Cancer in India175
Indian ABSI CS175 ABSI India 2017
145 Consensus document for management of breast cancer176 Indian ICMR CS176 ICMR India 2016
146 4th ESO–ESMO International Consensus Guidelines for 
Advanced Breast Cancer (ABC 4)177
ABC4177 ESMO Europe 2018
147 St. Gallen/Vienna 2019: A Brief Summary of the Consensus 
Discussion about Escalation and De-Escalation of Primary 
Breast Cancer Treatment178
St. Gallen 2019178 St. Gallen Europe 2019
148 ESTRO consensus guideline on target volume delineation for 
elective radiation therapy of early stage breast cancer179
ESTRO RT BC179 ESTRO Europe 2014
149 Second international consensus guidelines for breast cancer in 
young women (BCY2)180
BCY2180 ESO Europe 2016
150 Guidelines for diagnostics and treatment of aromatase 
inhibitor-induced bone loss in women with breast cancer 
A consensus of Lithuanian medical oncologists, radiation 
oncologists, endocrinologists, and family medicine 
physicians181
LOEGP181 LOEGP Lithuania 2014
151 Biomarkers in breast cancer: A consensus statement by the 
Spanish Society of Medical Oncology and the Spanish Society 
of Pathology182
SEOM and SEAP182 SEOM Spain 2017
152 Provincial consensus recommendations for adjuvant systemic 
therapy for breast cancer183
CCM 2017183 CCM Canada 2017
TA B L E  1   (Continued)
(Continues)
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Abbreviated name Entity Country Year
153 Postoperative radiotherapy for breast cancer: UK consensus 
statements184
RCR postoperative RT184 RCR UK 2016
154 Consensus Guideline on Accelerated Partial Breast 
Irradiation185
ASBS RT185 ASBS USA 2018
155 Consensus Guideline on the Use of Transcutaneous and 
Percutaneous Ablation for the Treatment of Benign and 
Malignant Tumors of the Breast186
ASBS ablation186 ASBS USA 2018
156 Consensus Guideline on the Management of the Axilla in 
Patients With Invasive/In-Situ Breast Cancer187
ASBS axilla187 ASBS USA 2019
157 Consensus Guideline on Breast Cancer Lumpectomy 
Margins188
ASBS margins188 ASBS USA 2017
158 Consensus Guideline on Concordance Assessment of Image-
Guided Breast Biopsies and Management of Borderline or 
High-Risk Lesions189
ASBS borderline lesions188 ASBS USA 2016
159 Contralateral Prophylactic Mastectomy (CPM) Consensus 
Statement from the American Society of Breast Surgeons: 
Data on CPM Outcomes and Risks190
ASBS CPM190 ASBS USA 2016
160 Consensus Guideline on Venous Thromboembolism (VTE) 
Prophylaxis for Patients Undergoing Breast Operations191
ASBS VTE prophylaxis BC191 ASBS USA 2011
161 The American Brachytherapy Society consensus statement on 
intraoperative radiation therapy192
AB intraoperative RT192 AB USA 2017
162 The American Brachytherapy Society consensus report 
for accelerated partial breast irradiation using interstitial 
multicatheter brachytherapy 193
AB partial RT BC193 AB USA 2017
163 Society of Surgical Oncology Breast Disease Working Group 




164 SSO-ASTRO Consensus Guideline on Margins for Breast-
Conserving Surgery with Whole-Breast Irradiation in Ductal 
Carcinoma In Situ195
SSO margins 195 SSO USA 2016
165 SSO-ASTRO Consensus Guideline on Margins for Breast-
Conserving Surgery with Whole Breast Irradiation in Stage I 
and II Invasive Breast Cancer196
SSO–ASTRO invasive BC196 SSO 
- ASTRO
USA 2014
166 Margins for Breast-Conserving Surgery With Whole-Breast 
Irradiation in Stage I and II Invasive Breast Cancer: American 
Society of Clinical Oncology Endorsement of the Society of 
Surgical Oncology/American Society for Radiation Oncology 
Consensus Guideline197
ASCO margin BC CSs197 ASCO USA 2014
167 International expert panel on inflammatory breast cancer: 
consensus statement for standardized diagnosis and 
treatment198
International expert panel 
BC198
IEP International 2010
TA B L E  1   (Continued)
Characteristics
CPGs or CSs without SDM
(n = 101)





Published after 2015 42 (42.0 %) 46 (69.7 %) .0003
CPG 83 (82.1 %) 54 (81.8 %) .95
European guidelines 45 (44.5 %) 25 (37.0 %) .21
North American guidelines 43 (42.5 %) 28 (42.4 %) .98
South American guidelines 2 (1.9 %) 5 (7.5 %) .1
Asia guidelines 9 (8.9 %) 3 (4.5 %) .15
Oceania guidelines 3 (2.9 %) 3 (4.5 %) .3
Published in a journal 44 (43.5 %) 17 (25.7 %) .009
TA B L E  2   Characteristics of the CPGs 
and CSs regarding SDM
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3.4 | SDM in CPGs and CSs concerning BC
The analysis of the compliance of the items valued is presented in 
Figure 2 and Appendix 4. SDM appeared in any section of 66 CPGs 
and CSs (12/28 (43%) CSs vs 54/139 (39%) CPGs, P = .69). SDM 
appeared in glossary or indexes in only two documents, and only in 
one, its basis was explained. In general, CSs had higher overall qual-
ity than CPGs (CSs' mean 2.833 vs CPGs' mean 1.12 items, P < .001) 
(Appendix ).
Overall, 39 (23%) stated the value of SDM as an option in the 
decision-making process, 14 (8%) provided clear and precise SDM 
recommendations, 4 (3%) considered benefits versus harms of using 
SDM, and 4 (2%) identified evidence supporting the use of SDM. 
Only 9 (5%) of these CPGs and CSs gave advice for the SDM appli-
cation in practice. The strength of recommendations on SDM was 
indicated in three (2%). Support for the implementation of SDM 
was well-detailed in two documents (1%). The information gath-
ered about SDM affected recommendations and was detailed in one 
(<1%). Limitations of the CPG or CS about SDM recommendations 
were described in just one of them (<1%).
Only 4 (2%) of these guides emphasized their interest in SDM ap-
pearing in the executive summary. Only in three (2%) of the CPGs and 
CSs, the table of content talked about SDM. Primary affected pop-
ulation with BC was well-defined in 22 (13%) articles, and patients’ 
subgroups with special consideration were discussed in 7 (4%) docu-
ments. Appropriateness and relevance of outcomes were considered 
in only 2 (1%) CPGs. Only one document detailed the consistency of 
results across studies. Recommendations about SDM for subgroups 
were separated in only two articles (1%). Facilitators and barriers to 
SDM application were described in only two articles too (1%).
Ten items (32%) measured in the data extraction instrument 
were not included in any CPGs and CSs (n = 10/31). The PICO 
question related to SDM was not specified, search strategy was 
not reported, the study design and limitations were not pondered, 
barriers were not described, the cost of SDM implementation was 
not specified, adherence to recommendations and the impact were 
not assessed, description of the cost information and suggestions for 
further research were not provided and finally, professional, finan-
cial or intellectual interest about SDM was not described (Figure 2 
and Appendix ). Finally, there were 101 (61%) CPGs or CSs did not 
talk about SDM.
All three reviewers categorized that the 'Alberta Health 
Services'88, 'Australian Government'155, 'Ministry of Health from 
New Zealand'165 and Costa Rica 'IHCAI'162 CPGs and 'CMCCR'172 CS 
had the highest overall quality in analysing the decision-making pro-
cess in BC treatment (Appendix ). In the United States of America, 
we highlighted two of the 'American Society of Clinical Oncology 
(ASCO)'140-148 guidelines and the last version of NCCN153, but 
with a lower mark if you compare with the ones we named before. 
In Europe, we found the 'European Society for Medical Oncology 
(ESMO)'41, the 'Asociación Española de Cirujanos (AEC)'80 and the 
'ABS-BAPRAS'118 CPGs with a score of 6 as the best paradigm of a 






























































































































































































































































14  |     MAES-CARBALLO Et AL.
F I G U R E  2   The analysis of the compliance of the data extraction items
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4  | DISCUSSION
4.1 | Main findings
We developed a standardized quality assessment tool for assessing 
the coverage of SDM in recommendation documents. Our review 
and analysis showed that SDM description, clarification and recom-
mendations CPGs and CSs concerning BC treatment were poor, leav-
ing a large scope for improvement in this area. SDM more frequently 
reported in CPGs and CSs in recent years but surprising SDM was 
less often covered in medical journals (Figure 3).
4.2 | Strengths and weaknesses
The validity of findings depends on the strength and limitations 
of methods, which should be understood first before assessing 
their implications202. A key strength of this study was a global 
perspective with a big number of CPGs and CSs included, without 
language restrictions or data sources limitations. We developed 
and deployed a prospective protocol with a specific SDM quality 
assessment tool incorporating the AGREE II instrument201, RIGHT 
statement200 and other related papers 9,21,24,25,27. Unfortunately, 
as there were no other similar studies, we could not compare our 
results with other findings. There have been evaluations of risk of 
bias in other papers, but our focus was on examining the report-
ing of guidance about SDM. One perceived limitation of this study 
could be related to the subjective nature of the data extraction; 
however, as we used duplicate data extraction with arbitration, we 
minimized this methodological issue. Quality assessment tool per-
formance may be a further issue, and we addressed this by follow-
ing a standard methodology for tool development. Not all quality 
items can have the same relevance and weight, and future research 
should focus on scoring them creating a threshold for rating quality. 
Because the items mainly came from two wide-used indexes200,201, 
demonstrably our tool should be considered to have face validity. 
Therefore, we are confident that our finding of poverty of SDM in-
formation in practice recommendations is trustworthy and merits 
further consideration.
Inter-examiner reliability should be calculated in systematic 
reviews as the data extracted should be the same by different re-
viewers203. Intra-examiner reliability is a pre-condition for inter-ob-
server reliability, and so was not calculated or reported31. In our 
paper, the inter-examiner reliability score was found to be excellent 
(ICC = 0.97).
4.3 | Implications
To our knowledge, information and recommendations about SDM in 
BC CPGs and CSs have not been systematically analysed previously. 
Neither did we find a tool to evaluate SDM reporting quality. This is 
surprising because SDM is a legal obligation11-13 and a key compo-
nent for high-quality patient-centred cancer care6-10.
Breast cancer is the paradigm of the situation where a two-way 
exchange not only of information but also of treatment preferences 
is needed to find the best option for a particular patient, as different 
strategies may show a priori similar advantages and disadvantages 
but possible outcomes are deeply related to the patient’s values and 
personal situation10,203.
Formal recommendations should promote SDM application in 
clinical routine practice, but this has proved difficult and slow18-
21,23,24. It would require changing attitudes, acquiring new skills, 
developing specific tools and ensuring an environment where com-
munication and sharing perspectives are valued10,21,25-27. Effective 
implementation strategies could be underpinned by SDM detailed 
in CPGs and CSs as these documents should be expected to provide 
this specific content11-13. Our work has identified a gap that offers 
an important contribution in directing further research and debate, 
including assessment of risk of bias in guidelines. It highlights the 
need for more objective-specific tools for SDM assessment, evalu-
ation of their psychometric properties and promotion in CPGs and 
F I G U R E  3   Comparison between the 
year of publication of the guide according 
to whether or not SDM appearance
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CSs for diverse malignancies. Future studies should be required in 
that direction.
5  | CONCLUSIONS
This systematic review found that BC treatment CPGs and CSs in-
sufficiently addressed SDM. Implementation of this practice is im-
portant for high-quality patient-centred cancer care, but lack of 
knowledge is a known barrier. SDM descriptions and recommen-
dations in CPGs and CSs concerning BC treatment need improve-
ment. SDM was more frequently reported in CPGs and CSs in recent 
years, but surprisingly it was less often covered in medical journals, 
a feature that needs attention. In the future, SDM should be suitably 
explained and encouraged and specific tools should be applied to 
assess its dealing and promotion in specific cancer treatment CPGs 
and CSs. Medical journals should play a strong role in promoting 
SDM in CPGs and CSs they publish in the future.
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